Rankings
▼
Calendar
▼
AIDX Q3 2024 Earnings Report — 20/20 Biolabs, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
20/20 Biolabs, Inc. Common Stock
AIDX
Q3 2024 Earnings
Reported September 29, 2024
Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
EPS (Diluted)
Metric
Q3 2024
Q2 2024
Q3 2023
QoQ Change
YoY Change
Revenue
$361.0K
—
—
—
—
Op. Income
-$2M
—
—
—
—
Gross Margin
6.7%
—
—
—
—
Net Margin
-519.0%
—
—
—
—
EPS (Diluted)
$-0.39
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$361.0K
Cost of Revenue
$336.9K
GROSS PROFIT
$24.1K
R&D Expenses
$297.1K
Selling & Marketing
$0
General & Administrative
$0
SG&A Expenses
$2M
Other Expenses
$0
Operating Expenses
$2M
Cost & Expenses
$2M
OPERATING INCOME
-$2M
Interest Income
$16.9K
Interest Expense
$0
Other Income/Expenses
$16.9K
INCOME BEFORE TAX
-$2M
Income Tax Expense
$0
Net Income from Continuing Ops
-$2M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$2M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$2M
D&A
$34.1K
EBIT
-$2M
EBITDA
-$2M
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
← FY 2024
AIDX Overview
Q4 2024 →